SUMMARY A double blind randomised study was undertaken comparing the effects of oral mexiletine and placebo given by general practitioners at home in the early stages of suspected acute myocardial infarction, and continued for six weeks. The study comprised 216 patients. In 59 the diagnosis of acute myocardial infarction was not confirmed. Of the 72 patients with confirmed myocardial infarction treated with mexiletine, 11 (15.3%) died, compared with 19 (22.4%) of the 85 patients given the placebo, and significantly fewer of the former compared with the latter had frequent ventricular ectopics or ventricular tachycardia recorded on 24 hour electrocardiograms. Numbers of patients transferred to hospital or withdrawn from the trial because of arrhythmia or heart failure were similar in the two treated groups. Ten (13.9%) of the patients taking mexiletine had the drug withdrawn because of side effects attributed to it, compared with three (3.5%) of the group taking the placebo. A further five patients (all on mexiletine) also had treatment withdrawn because of side effects but infarction was not later confirmed. The results indicate that oral mexiletine can be given safely to patients with suspected myocardial infarction at home by their general practitioners in the absence of a positive electrocardiographic diagnosis. The frequency of ventricular tachycardia is significantly reduced; but there is no evidence of reduced mortality.
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Precise figures are not available for the proportion of patients with acute myocardial infarction cared for at home in the UK. There is no reason to believe that the proportion of one-third found in the Teesside survey in 1976' is unusual. Sudden unexpected death from ventricular fibrillation occurs in patients looked after at home just as it does in hospital.
Apart from one study2 using intramuscular lignocaine prophylactically for (3) Ischaemic heart disease: A good previous history of ischaemic heart disease but no evidence for fresh myocardial infarction.
(4) Other
For the purposes of this study, patients in categories 1 and 2 were considered as having suffered an acute myocardial infarction and this was assumed in those dying at home after taking the trial tablets but before the visit of the trial doctor. Patients in categories 3 and 4 were withdrawn from treatment as were those transferred to hospital, those with arrhythmias requiring treatment, and those with shock, coma, severe intercurrent illness, unacceptable side effects, or who were otherwise unable to take drugs orally. All such patients withdrawn from treatment were questioned at six weeks about side effects and were included in the analysis of results. Details concerning the patients who died during the six week study period were obtained from the general practitioner or occasionally the relatives. Deaths were classified as being either sudden or occurring in the context of a gradual deterioration.
Serum cardiac enzyme concentrations were estimated in the Department of Clinical Chemistry, Royal Berkshire Hospital, with upper limits of normal of 40 U (AST) and 250 U (LDH). Plasma mexiletine concentrations were measured using a specific gasliquid chromatographic technique.5 Twenty-four hour tape recordings were analysed on a Reynolds High Speed ECG Analyser by a trained observer who did not know which patients had been treated. Tapes with less than eight hours' analysable electrocardiogram were rejected. Ventricular arrhythmias were classified as ventricular extrasystoles (aberrant beats not preceded by P waves), frequent ventricular extrasystoles (>30 per hour), R on T (RRV/ QT-0.85), multifocal (two or more morphologies in any hour), couplets (two consecutive ventricular beats separated by not more than 400 ms), ventricular tachycardia (three or more consecutive ventricular beats at a heart rate more than 150 beats a minute), prolonged ventricular tachycardia (more than 10 beats a salvo), and frequent ventricular tachycardia (more than three runs in any tape). A pause was defined as a gap of 1500 ms separating two consecutive beats.
Significance testing for the differences in mortality, additional treatment received, incidence of arrhythmias, and side effects in the two groups was done using the x2 test, with Yates' correction. The Mann-Whimtney U test was used for testing the significance of the differences in numbers of extrasystoles and enzyme levels between the two groups. Simple linear regression was used to test the correlation of blood levels with age. dial infarction. Table 1 shows the classification of the trial entrants according to our four diagnostic categories. Table 2 shows the baseline clinical details of the patients with myocardial infarction according to treatment group. Table 3 shows the electrocardiographic details and median peak cardiac enzymes in the two treatment groups. There were no significant differences between the two treatment groups for any of these criteria, and, other than oral analgesics which were given more frequently (p<005) within three hours of the loading dose to patients taking mexiletine, there were no differences in concurrent drug administration. Apart from beta blockers being taken by 12 out of 113 (10.6%) having placebo and 10 out of 103 (9.7%) having mexiletine, no patients were receiving any other antiarrhythmic drug. Eleven patients (seven placebo, four mexiletine) with assumed myocardial infarction died suddenly after entry but before being seen by the project doctor. In one of these an electrocardiogram taken by the general practitioner showed early changes of infarction, but the remaining 10 patients had no electrocardiographic or enzyme evidence collected before sudden death after a story of typical chest pain.
No patients died between the project doctor's two visits while on the 24 hour electrocardiograph recorder. Six patients died after the project doctor's second visit while still in the trial, three suddenly (two taking placebo, one taking mexiletine) and three after gradual deterioration with heart failure (one taking placebo, two taking mexiletine). Of the withdrawals, nine patients with confirmed infarction on placebo died during the six week period (four suddenly and five in heart failure), compared with four on mexiletine (two suddenly and two in heart failure). Fourteen patients died suddenly while taking treatment (nine taking placebo and five taking mexiletine) (NS).
WITHDRAWALS
Forty-three (27%) patients with confirmed myocardial infarction were withdrawn for reasons given in Table  5 . Twenty-four of these (14 taking placebo, 10 taking mexiletine) were transferred to hospital, mostly because of continuing chest pain or heart failure (10 taking placebo, eight taking mexiletine) and none solely because of side effects.
SIDE EFFECTS
By the second day of the trial doctor's visit 37 of 216 (24) 2 (5) (f) frequent ventricular tachycardia
(h) ventricular fibrillation 0 (0) 1 (3) *** p < 0-01 ** p < 0-05
respectively. The median delay between the onset of symptoms to the start of the tapes was 26 hours for the placebo group and 29 hours for the mexiletine group. The abnormalities found on the 24 hour electrocardiogram are shown in Table 6 . Patients with confirmed myocardial infarction taking mexiletine had fewer ventricular extrasystoles than those taking placebo (median ectopic count per hour 2-63 versus 6-09, p<0-05). Serious ventricular arrhythmias, including frequent ventricular extrasystoles and ventricular tachycardia, were seen more frequently in patients in the placebo group. No differences were seen between the two groups in the incidence of pauses or supraventricular arrhythmnias including atrial fibrillation. The median number of ventricular extrasystoles per hour in the 12 of the 50 patients taking placebo who had ventricular tachycardia was 14-34 compared with 3-02 in the other 38 who did not have this arthythmia (p<0-01). Similarly, in the former, frequent ventricular extrasystoles (nine out of 12 compared with 11 out of 38, p<0-05) and couplets (12 out of 12 compared with 14 out of 38, p<0-001) were seen more frequently. Of the 12 patients on placebo who had ventricular tachycardia, seven completed the six week study, three died during the trial, and two were withdrawn because of heart failure, one to die subsequently.
DRUG PLASMA LEVELS
The mean mexiletine concentrations for patients with confirmed myocardial infarction on days 1, 2, and 42 were 0X69 ,ug/ml, 1X00 ,ug/ml, and 0-82 ,ug/ml, respectively. Two patients supposedly taking mexiletine had an undetectable level on day 42 (lower limit of sensitivity for the assay 0.01 ug/ml). No significant correlation was found in patients with confirmed myocardial infarction between age and blood levels on day 1, 2, or 42.
There was no signifcant difference in the median number of extrasystoles per hour for patients with mexiletine concentrations (mean of day 1 The placebo mortality of 22*4% in the present study must be compared with a six week mortality of 24% in the Nottingham triall2 where 500/o of patients were seen within three hours of the onset of symptoms. In the Tees-side survey' the mortality in patients seen after three hours was 15% so our mortality falls between these two figures.
We have not shown a significant reduction in mortality in patients taking mexiletine; but the reduction in arrhythmias and the fewer sudden deaths in such patients are consistent with a therapeutic benefit. Furthermore, an analysis of the deaths, the 24 hour electrocardiographic recordings, and the reasons for withdrawal do not support the possibility that the patients were harmed by being given mexiletine. The reduction in frequency of ventricular ectopics and ventricular tachycardia in our study is in keeping with the known effects of mexiletine given after acute myocardial infarction.34 The effect of intravenous mexiletine on left ventricular function in normal man is slight'3 14 and in our patients the oral dosage used did not precipitate heart failure. The proportion of patients in the treatment group dying from heart failure was no more than in the placebo group, and the same was true for withdrawals from treatment because of heart failure. Similarly, our results make it unlikely that patients with atrioventricular or intraventricular conduction defects were harmed by mexiletine and this finding would support the data of McComish et al. ' 5 who reported shortening of the effective refractory period of the atrioventricular node and no effect on atrioventricular and His-Purkinje conduction time.
Published data suggest a minimum effective plasma concentration for mexiletine of 0 5 ,ug/mll6 while a range of 0-75 to 2*0 ,ug/ml is associated with a low incidence of side effects. '7 The mean plasma drug concentrations in our patients were satisfactory on days 1 and 2 and at completion. The lowest concentrations were recorded on day 1 and it is probable that in the first few hours some of our patients had subtherapeutic plasma concentrations of mexiletine. The fixed dose and loading regimen used ensured that in sick and elderly patients toxic levels were rarely found and our figures indicate that a larger loading dose could be given safely to patients at home not under observation.
The study demonstrates the problems of home coronary care. Our 216 patients were seen at a median time of five hours after the onset of symptoms.
Undoubtedly, general practitioners referred patients seen earlier to hospital rather than enter them into the trial. The overall diagnostic accuracy of the general practitioners was high and 73% of patients referred had myocardial infarction. Overall, 15% of patients with confirmed acute myocardial infarction for whom home care was intended had to be transferred to hospital.
The present study makes no attempt to compare the role of home versus hospital in coronary care. In rural communities and in cases where patients are seen initially a few hours after the onset of their symptoms, many general practitioners will elect to look after the patient at home. Though it may be premature to use prophylactic antiarrhythmic drugs in routine domiciliary practice, we cannot agree with Sloman's statement quoted recently in a leading article18 "it is inappropriate to use such drugs as disopyramide or mexiletine in an environment outside a Coronary Care Unit where drugs are being used which can interfere with conduction, and which may produce serious side effects". The mainly negative findings of previous studies in prophylactic antiarrhythmic therapy may not apply to home care, and now that we have shown it to be both practicable and safe further evidence should be sought with regard to the benefit from earlier prophylactic administration of mexiletine or a similar drug by general practitioners at home.
